ICI Pharma
Executive Summary
Files NDA for congestive heart failure therapy Carwin (xamoterol). Application for the beta agonist/beta antagonist includes 130 clinical studies involving 1,660 patients. Analyses of four pivotal Phase III trials "suggest that xamoterol improves functional capacity, quality of life, and clinical signs in patients with mild to moderate CHF," firm says.